We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Revises Guidance on Reporting Drug Impurities in ANDAs
FDA Revises Guidance on Reporting Drug Impurities in ANDAs
January 28, 2005
The FDA has made significant revisions to a November 1999 guidance that provides recommendations on the types of drug impurity data included with drug applications.